What is a malignant peripheral nerve sheath tumour?
A malignant peripheral nerve sheath tumour (MPNST) is a rare, fast-growing cancer that starts in the cells of the sheath that covers and protects the peripheral nerves. These are the nerves outside the brain and spinal cord. MPNST is a type of soft tissue sarcoma, and older names for it include malignant schwannoma and neurofibrosarcoma.
MPNST makes up about 5-10% of soft tissue sarcomas. Around half of all cases occur in people with the genetic condition neurofibromatosis type 1 (NF1), where the cancer usually grows out of a benign nerve tumour called a plexiform neurofibroma. The rest arise without a known cause or, less often, in an area treated with radiotherapy years earlier.
MPNST can grow into nearby tissues, often comes back after surgery and can spread to the lungs and other organs. The best chance of cure is early diagnosis and complete removal by an experienced sarcoma team.
1. How common is it?
| Feature | Details |
|---|---|
| Share of sarcomas | About 5-10% of soft tissue sarcomas |
| General population | Very rare; often quoted at about 1 in 100,000 people (0.001%) |
| People with NF1 | Lifetime risk of about 8-13% (8-16% in the European ERN GENTURIS guideline), compared with a tiny risk in the general population |
| Share linked to NF1 | About 25-50% of all MPNSTs |
| Age | Mostly young and middle-aged adults. In NF1 it usually appears at 20-40 years (median about 26 in one population study); sporadic cases are typically diagnosed later, often at 40-60 or older |
| Sex | Men and women are affected about equally |
| Sites | Limbs (about 45%), trunk (about 35%), head and neck (about 20%) in a large Mayo Clinic series; usually along large nerves such as the sciatic nerve, brachial plexus or spinal nerve roots |
2. Causes and risk factors
MPNST develops when nerve sheath cells (mainly Schwann cells) gain a series of genetic changes that let them grow out of control. Three main groups are recognised.
| Group | Share of cases | Key points |
|---|---|---|
| NF1-associated | About 25-50% | NF1 affects about 1 in 3,000 people. It is caused by an inherited or new change in the NF1 gene. Most MPNSTs in NF1 grow from a pre-existing plexiform neurofibroma, often via an atypical stage |
| Sporadic | About 40-60% | No inherited condition; the same genes are usually damaged, but only in the tumour cells |
| Radiation-associated | About 10% | Develops in a previously irradiated area, typically 10-20 years later (median about 15 years in one large series) |
2.1 How the cancer develops
Most MPNSTs share a typical sequence of gene changes:
| Step | Gene change | Effect |
|---|---|---|
| Benign neurofibroma | Loss of both copies of NF1 | Overactive RAS signalling and growth of a plexiform neurofibroma |
| Atypical neurofibroma (ANNUBP) | Loss of CDKN2A/B | Loss of a cell-cycle “brake”; the tumour becomes premalignant |
| MPNST | Loss of the PRC2 complex (SUZ12 or EED), often with TP53 changes | Loss of the H3K27me3 histone mark and full malignant behaviour |
In 2014, PRC2 loss was found in about 92% of sporadic, 70% of NF1-associated and 90% of radiation-associated MPNSTs.
2.2 People with NF1 at higher risk
The ERN GENTURIS guideline (2023) lists the following people with NF1 as being at particularly high risk of MPNST:
- People with an NF1 microdeletion (a missing stretch of chromosome that includes the SUZ12 gene).
- People with certain missense variants affecting codons 844-848 of the NF1 gene.
- People who have had an atypical neurofibroma (ANNUBP).
- People with a large internal tumour load on whole-body MRI, or large or multiple plexiform neurofibromas.
- People with neurofibromatous neuropathy.
- People who have had radiotherapy in the past.
- People with a relative who has NF1 and MPNST.
3. How does it look?
3.1 On the body
MPNST usually shows up as a deep, firm lump along the course of a nerve. It is often more than 5 cm across when first found. In people with NF1, it may appear as a change in a lump they already have.
| Situation | What may be noticed |
|---|---|
| Limb or trunk | A deep, growing lump in the thigh, buttock, upper arm, armpit or back, often painful and fixed to the tissues around it |
| Neck or brachial plexus | A firm swelling at the side of the neck or above the collarbone, sometimes with arm pain or weakness |
| Plexiform neurofibroma in NF1 | A previously soft, stable neurofibroma that grows quickly, becomes hard or nodular, or starts to hurt |
| Pelvis, abdomen or chest | Often nothing visible until the tumour is large; the first signs may be pain, swelling or nerve problems |
| Skin | Usually normal; large tumours may stretch the skin, and some people with NF1 have cafe-au-lait spots and skin neurofibromas |
3.2 On scans
| Test | Typical findings |
|---|---|
| MRI with contrast | A large mass along a nerve, often with uneven enhancement, central dead tissue (necrosis), blurred edges and swelling around it. Features that raise suspicion in NF1 include size over 5 cm, loss of the “target sign” of benign neurofibromas and a new nodule within a plexiform neurofibroma |
| FDG PET-CT or PET-MRI | MPNSTs usually take up much more of the radioactive sugar tracer than benign neurofibromas. In a long-term study of people with NF1, FDG PET had a sensitivity of 89% and a specificity of 95% for MPNST |
| CT of the chest | Checks for spread to the lungs, the most common site of metastasis |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Tightly packed spindle-shaped cells in long bundles, with alternating crowded and looser areas (“marbled” pattern) |
| Nuclei | Dark, irregular, often wavy or bullet-shaped |
| Activity | Frequent cell divisions and areas of necrosis in high-grade tumours |
| Special forms | Malignant triton tumour (with muscle-like cells), MPNST with gland-like or bone/cartilage elements, and epithelioid MPNST (rounder cells, a distinct subtype that is rarely linked to NF1) |
3.4 Special stains and tests
| Marker | Typical result | Why it matters |
|---|---|---|
| H3K27me3 | Complete loss in about half to two-thirds of MPNSTs: about 50% in one Harvard series and about 61% (69% including partial loss) in one Memorial Sloan Kettering series. More frequent in high-grade (about 83%) and radiation-associated tumours; in some series less frequent in NF1-associated tumours | Loss is highly specific: benign neurofibromas, schwannomas and most mimics keep the mark. A retained stain does not rule out MPNST |
| S100 protein and SOX10 | Positive in only about half of cases, usually patchy | Supports nerve sheath origin; strong, diffuse staining suggests a schwannoma or melanoma instead |
| p16/CDKN2A | Often lost | Supports malignant change; can already be lost in atypical neurofibromas |
| Ki-67 and p53 | High proliferation index; strong p53 in a subset | Support malignancy |
| SMARCB1 (INI1) | Usually kept in conventional MPNST; lost in about 70% of epithelioid MPNSTs | Helps identify the epithelioid subtype |
| Molecular tests | Fusion tests negative | Exclude mimics such as synovial sarcoma (SS18 fusion) |
Epithelioid MPNST is different: it is strongly and diffusely positive for S100 and SOX10 and keeps H3K27me3.
3.5 From benign to malignant in NF1
An international consensus (2017) introduced the term atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP). It describes a neurofibroma with at least two worrying features: nuclear atypia, loss of the normal neurofibroma pattern, high cellularity, or mitotic activity above 1 per 50 but below 3 per 10 high-power fields.
ANNUBP is regarded as a premalignant stage. Low-grade MPNST shows similar features with 3-9 mitoses per 10 high-power fields and no necrosis. Most MPNSTs, however, are high-grade at diagnosis.
4. Symptoms
Early MPNST may cause no symptoms. As it grows, the most common complaints are pain, a growing lump and nerve problems in the area supplied by the affected nerve.
| Type of symptom | Examples |
|---|---|
| Lump | A deep, firm swelling that grows over weeks to months |
| Pain | Persistent pain in or around the lump, often worse at night and not relieved by usual painkillers |
| Nerve symptoms | Shooting pain along the nerve, tingling or numbness, muscle weakness (for example foot drop when the sciatic nerve is affected) |
| Pressure on nearby structures | Limb swelling; in the neck, difficulty swallowing or breathing; in the pelvis or spine, bladder or bowel problems |
| General symptoms | Tiredness, weight loss or shortness of breath, mainly with advanced or spreading disease |
Warning signs for people with NF1
The ERN GENTURIS guideline advises that people with NF1 should be checked for MPNST if they notice:
- Rapid growth of a plexiform neurofibroma, or a change in how fast it grows.
- New, persistent pain, especially pain at night or pain that is hard to control.
- New weakness, numbness or loss of feeling linked to a neurofibroma or nerve.
- Bladder or bowel changes, or problems with swallowing or breathing.
- A new hard nodule in a previously soft plexiform neurofibroma.
See a doctor promptly for any of these. Because MPNST can grow quickly, delays of even a few months can make treatment harder.
5. Diagnosis
| Test | Purpose |
|---|---|
| Clinical examination | Size, depth and firmness of the lump; nerve function (strength, feeling, reflexes); signs of NF1 |
| MRI with contrast | Shows the size and exact position of the tumour and its relation to nerves, blood vessels and bone; used to plan biopsy and surgery |
| FDG PET-CT or PET-MRI | In NF1, recommended before surgery on a suspicious tumour to find the most active part and to tell malignant change from a benign plexiform neurofibroma. It also helps with staging |
| Image-guided core needle biopsy | Confirms the diagnosis. In NF1, the biopsy should target the most PET-active area because the tumour can be patchy, and a negative result does not always exclude cancer |
| Pathology review | By a sarcoma pathologist, including H3K27me3, S100, SOX10 and other markers to rule out mimics |
| CT of the chest | Looks for lung metastases |
| Genetic testing | NF1 testing for people with signs of NF1 or a family history; genetic counselling for relatives |
The biopsy and surgery should be planned and done at a sarcoma reference centre. A poorly placed biopsy or an unplanned removal (“whoops” excision) can make later curative surgery more difficult.
Staging
MPNST is staged like other soft tissue sarcomas, using the AJCC 8th edition system for trunk and limb sarcomas.
| Factor | What is assessed |
|---|---|
| T (tumour size) | T1 up to 5 cm; T2 over 5 to 10 cm; T3 over 10 to 15 cm; T4 over 15 cm |
| N (lymph nodes) | Spread to nearby lymph nodes is uncommon |
| M (metastasis) | Spread to distant organs, mainly the lungs |
| Grade | Low, intermediate or high (FNCLCC system); most MPNSTs are high grade |
In simple terms, stage I is a low-grade tumour that has not spread, and stages II-III are higher-grade tumours that have not spread, with larger tumours given a higher stage. Stage IV means spread to lymph nodes or distant organs.
6. Treatment
Treatment should be planned by a multidisciplinary sarcoma team that includes a sarcoma surgeon, an oncologist, a radiation oncologist, a pathologist, a radiologist and, for people with NF1, an NF1 specialist. European (ESMO-EURACAN-GENTURIS) and NF1 (ERN GENTURIS) guidelines agree that complete surgical removal with wide margins is the mainstay of curative treatment.
6.1 Surgery
| Aspect | Details |
|---|---|
| Aim | Remove the whole tumour with a layer of healthy tissue around it (wide resection), leaving no tumour cells at the edges (R0) |
| Affected nerve | The nerve of origin often has to be removed with the tumour. Nerve grafts, nerve or tendon transfers and splints can help to restore function |
| Limb-sparing surgery | Possible for most limb tumours; amputation is needed only rarely, when no other way to remove the tumour completely exists |
| Difficult sites | Tumours of the spine, pelvis, head and neck or trunk are harder to remove with clear margins, so local recurrence is more common |
| Atypical neurofibroma (ANNUBP) in NF1 | Removal is recommended if safe and feasible, as it seems to prevent further malignant change |
Clear margins are one of the strongest factors for local control and survival.
6.2 Radiotherapy
Radiotherapy is used together with surgery for most tumours that are high grade, deep or larger than 5 cm.
| Use | Usual approach | Points to know |
|---|---|---|
| Before surgery (pre-operative) | About 50 Gy in 25 daily treatments; surgery follows a few weeks later | Smaller treatment area and less long-term stiffness and swelling, but more wound-healing problems |
| After surgery (post-operative) | About 60-66 Gy | Used when radiotherapy was not given first, or when margins are close or positive. In a large Massachusetts General Hospital series, adding radiotherapy improved local control after incomplete resection |
| Palliative | Shorter courses | Relieves pain or pressure from tumours that cannot be removed or have spread |
Possible side effects include skin reactions, tiredness, stiffness, swelling of the limb, wound problems and, rarely, a new sarcoma years later. In people with NF1, radiotherapy is used carefully because they may be more prone to radiation-induced tumours.
6.3 Chemotherapy
MPNST responds only moderately to chemotherapy. It is used mainly for tumours that cannot be removed, for high-risk tumours before surgery (neoadjuvant treatment), and for cancer that has spread.
| Treatment | How it is given | Evidence and side effects |
|---|---|---|
| Doxorubicin plus ifosfamide | Drip over several days every 3 weeks, in hospital; mesna is given to protect the bladder | Most active first-line combination. In pooled EORTC trials, the response rate in advanced MPNST was 21% overall, similar to other sarcomas, and best with doxorubicin-ifosfamide. In the SARC006 trial, tumours shrank in about 18% of people with NF1 and 44% of people with sporadic MPNST. Side effects include hair loss, nausea, low blood counts and infection risk, kidney and bladder effects, confusion (ifosfamide) and heart damage (doxorubicin) |
| Doxorubicin alone | Drip every 3 weeks | For people who cannot have ifosfamide; fewer side effects but lower response |
| Ifosfamide with etoposide | Drip over several days | Sometimes used alternately with doxorubicin-ifosfamide, as in the SARC006 trial |
| Other drugs (e.g. gemcitabine-docetaxel, trabectedin) | Drip | Limited activity in MPNST; used after first-line treatment fails |
6.4 Targeted treatment and clinical trials
There is no approved targeted drug for MPNST yet. Clinical trials are testing drugs aimed at the changes found in MPNST, such as MEK inhibitors combined with other drugs, immunotherapy and epigenetic drugs. People with advanced MPNST should ask about trials at a sarcoma centre.
The MEK inhibitors selumetinib and mirdametinib are approved to shrink inoperable, symptomatic plexiform neurofibromas in NF1. They treat these benign tumours and are not a treatment for MPNST.
6.5 Follow-up
| Period | Typical schedule |
|---|---|
| First 2-3 years | Examination, MRI of the tumour area and chest CT about every 3-4 months, when most recurrences occur |
| Years 3-5 | About every 6 months |
| After 5 years | Once a year |
People with NF1 also need lifelong NF1 follow-up, including checks of any remaining plexiform neurofibromas.
7. Outlook
MPNST is a serious cancer, but people whose tumour is found early and removed completely can be cured. According to the US National Cancer Institute, 5-year survival ranges from about 23% to 69%, depending mainly on tumour size, site and whether the cancer has spread.
| Factor | Effect on outlook |
|---|---|
| Tumour size | Tumours under 5 cm do much better; in the Mayo Clinic series, size of 5 cm or more was a strong predictor of death from MPNST |
| Grade | High-grade tumours carry a higher risk of spread |
| Margins | Complete (R0) removal gives the best local control and survival |
| Site | Limb tumours do better than tumours of the trunk, spine or pelvis |
| Spread at diagnosis | Survival is much shorter; in pooled EORTC trials of advanced disease, median survival with chemotherapy was about 1 year |
| NF1 | Older studies found worse survival in NF1 (for example 21% versus 42% at 5 years in one English population study). A 2013 meta-analysis showed that the gap has been narrowing, and treatment should not depend on NF1 status |
| Radiation-associated MPNST | Tends to have a poorer outlook than sporadic MPNST |
In the Mayo Clinic series of 175 people treated in a specialist centre, 5-year disease-specific survival was 60% and local recurrence occurred in 22%. The lungs are the most common site of spread, followed by bone and the pleura.
8. Living with MPNST
- Rehabilitation: physiotherapy and occupational therapy help with strength, movement and daily tasks after surgery or nerve loss. Splints or braces may help with weakness, such as foot drop.
- Pain: nerve pain is common. Medicines for nerve pain, physiotherapy and pain-clinic support can help.
- Emotional support: fear of recurrence is common. Counselling, psycho-oncology services and patient groups can help.
- Fertility: chemotherapy can affect fertility. Ask about sperm or egg storage before treatment starts.
- For families with NF1: genetic counselling explains the 50% chance of passing NF1 on to each child, and the options available.
- Support organisations: the Children’s Tumor Foundation (NF1) and Sarcoma Patients EuroNet provide information and peer support.
9. Frequently asked questions
| Question | Answer |
|---|---|
| Is MPNST the same as a neurofibroma? | No. Neurofibromas are benign nerve tumours. MPNST is a cancer, although in NF1 it often develops from a plexiform neurofibroma |
| Will everyone with NF1 get MPNST? | No. The lifetime risk is about 8-16%, so most people with NF1 never develop it. Knowing the warning signs is important |
| Can MPNST be prevented? | Sporadic MPNST cannot be prevented. In NF1, checking plexiform neurofibromas regularly and removing atypical neurofibromas early may prevent some cancers |
| Is MPNST inherited? | MPNST itself is not inherited, but NF1 is. A child of a parent with NF1 has a 50% chance of having NF1 |
| Will I lose the use of my limb? | Most people keep their limb. Function depends on which nerve is involved; rehabilitation and reconstructive surgery can help |
| Should I join a clinical trial? | Trials are an important option, especially for advanced MPNST, because standard drug treatment has limited effect |
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Evans, D.G.R. et al. (2002) ‘Malignant peripheral nerve sheath tumours in neurofibromatosis 1’, Journal of Medical Genetics, 39(5), pp. 311-314.
- Ferner, R.E. and Gutmann, D.H. (2002) ‘International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis’, Cancer Research, 62(5), pp. 1573-1577.
- Lee, W. et al. (2014) ‘PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors’, Nature Genetics, 46(11), pp. 1227-1232.
- Schaefer, I.M., Fletcher, C.D. and Hornick, J.L. (2016) ‘Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics’, Modern Pathology, 29(1), pp. 4-13.
- Prieto-Granada, C.N. et al. (2016) ‘Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST’, American Journal of Surgical Pathology, 40(4), pp. 479-489.
- Schaefer, I.M. et al. (2019) ‘Recurrent SMARCB1 inactivation in epithelioid malignant peripheral nerve sheath tumors’, American Journal of Surgical Pathology, 43(6), pp. 835-843.
- Miettinen, M.M. et al. (2017) ‘Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1 – a consensus overview’, Human Pathology, 67, pp. 1-10.
- Ferner, R.E. et al. (2008) ‘[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study’, Annals of Oncology, 19(2), pp. 390-394.
- Carton, C. et al. (2023) ‘ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1’, EClinicalMedicine, 56, 101818.
- Legius, E. et al. (2021) ‘Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation’, Genetics in Medicine, 23(8), pp. 1506-1513.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Kroep, J.R. et al. (2011) ‘First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study’, Annals of Oncology, 22(1), pp. 207-214.
- Higham, C.S. et al. (2017) ‘SARC006: phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naive malignant peripheral nerve sheath tumors’, Sarcoma, 2017, 8685638.
- Stucky, C.C. et al. (2012) ‘Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience’, Annals of Surgical Oncology, 19(3), pp. 878-885.
- Kolberg, M. et al. (2013) ‘Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1’, Neuro-Oncology, 15(2), pp. 135-147.
- Miao, R. et al. (2019) ‘Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST’, Radiotherapy and Oncology, 137, pp. 61-70.
- National Cancer Institute (2020) Malignant Peripheral Nerve Sheath Tumor. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/mpnst (Accessed: October 2026).
- Children’s Tumor Foundation (2026) Neurofibromatosis type 1 (NF1). Available at: https://www.ctf.org/understanding-nf/nf1 (Accessed: October 2026).
Prepared by the editorial team, October 2026.